Mind Medicine (MindMed) (NASDAQ:MNMD) Shares Up 10.1% - What's Next?

Shares of Mind Medicine (MindMed) Inc. (NASDAQ:MNMD - Get Free Report) were up 10.1% during mid-day trading on Thursday . The stock traded as high as $7.51 and last traded at $7.43. Approximately 349,496 shares changed hands during mid-day trading, a decline of 75% from the average daily volume of 1,385,982 shares. The stock had previously closed at $6.75.

Analysts Set New Price Targets

A number of research analysts have issued reports on MNMD shares. Leerink Partnrs raised Mind Medicine (MindMed) to a "strong-buy" rating in a research note on Friday, October 11th. Canaccord Genuity Group lowered their target price on Mind Medicine (MindMed) from $16.00 to $14.00 and set a "buy" rating for the company in a research note on Monday, September 16th. HC Wainwright raised their target price on shares of Mind Medicine (MindMed) from $35.00 to $55.00 and gave the stock a "buy" rating in a report on Thursday, August 29th. Roth Capital upgraded shares of Mind Medicine (MindMed) to a "strong-buy" rating in a report on Wednesday, July 24th. Finally, Leerink Partners initiated coverage on shares of Mind Medicine (MindMed) in a research report on Monday, October 14th. They issued an "outperform" rating and a $20.00 price objective on the stock. Nine equities research analysts have rated the stock with a buy rating and three have given a strong buy rating to the stock. Based on data from MarketBeat.com, Mind Medicine (MindMed) currently has an average rating of "Buy" and a consensus target price of $25.38.

Mind Medicine (MindMed) Trading Up 14.1 %

The firm has a market cap of $555.52 million, a price-to-earnings ratio of -3.03 and a beta of 2.48. The company has a debt-to-equity ratio of 0.12, a current ratio of 5.92 and a quick ratio of 5.92. The business has a 50-day moving average of $6.01 and a 200-day moving average of $7.24.

Mind Medicine (MindMed) (NASDAQ:MNMD - Get Free Report) last released its quarterly earnings data on Tuesday, August 13th. The company reported ($0.48) EPS for the quarter, missing the consensus estimate of ($0.30) by ($0.18). Research analysts anticipate that Mind Medicine will post -1.27 EPS for the current year.

Insider Activity at Mind Medicine (MindMed)

In other Mind Medicine (MindMed) news, CEO Robert Barrow sold 19,771 shares of the business's stock in a transaction that occurred on Wednesday, September 25th. The stock was sold at an average price of $5.98, for a total transaction of $118,230.58. Following the transaction, the chief executive officer now owns 545,772 shares of the company's stock, valued at $3,263,716.56. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other Mind Medicine (MindMed) news, insider Dan Karlin sold 6,871 shares of the firm's stock in a transaction that occurred on Wednesday, September 25th. The shares were sold at an average price of $5.98, for a total transaction of $41,088.58. Following the completion of the sale, the insider now directly owns 344,656 shares in the company, valued at $2,061,042.88. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Robert Barrow sold 19,771 shares of the company's stock in a transaction that occurred on Wednesday, September 25th. The shares were sold at an average price of $5.98, for a total value of $118,230.58. Following the completion of the transaction, the chief executive officer now directly owns 545,772 shares in the company, valued at $3,263,716.56. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 28,994 shares of company stock worth $173,384. Insiders own 2.26% of the company's stock.

Hedge Funds Weigh In On Mind Medicine (MindMed)

Several institutional investors and hedge funds have recently modified their holdings of MNMD. SageView Advisory Group LLC acquired a new position in Mind Medicine (MindMed) in the first quarter valued at about $25,000. Wealth Enhancement Advisory Services LLC acquired a new position in shares of Mind Medicine (MindMed) in the 3rd quarter valued at approximately $58,000. Bridgewealth Advisory Group LLC bought a new stake in shares of Mind Medicine (MindMed) during the 2nd quarter worth approximately $72,000. Wealth Alliance bought a new position in Mind Medicine (MindMed) in the second quarter valued at approximately $79,000. Finally, SG Americas Securities LLC acquired a new position in Mind Medicine (MindMed) during the third quarter valued at approximately $93,000. 27.91% of the stock is currently owned by institutional investors and hedge funds.

Mind Medicine (MindMed) Company Profile

Mind Medicine (MindMed) Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.